Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-444

Sarepta´s only marketed drug eteplirsen is still at high risk if it fails in Phase 3 trial then it could be GAME OVER for them . Dont forget that we have the former Chairman of Sarepta on our board so the likelihood that this company getting bought is very HIGH especially as long as the share price trading at this brutally discount .


https://seekingalpha.com/news/3492298-sarepta-launch-late-stage-study-high-dose-eteplirsen

The FDA initially approved the drug, branded as EXONDYS 51, almost three years ago under accelerated review status with the requirement that the company conduct a pivotal Phase 3 study to prove efficacy and secure full approval. Failure to demonstrate a statistically valid treatment benefit would potentially be the basis for withdrawing the product from the U.S. market.